It is common to see patients with atherosclerotic coronary disease and peripheral arterial disease in routine clinical practice. One needs to have a comprehensive and integrated multi-speciality approach and panvascular revascularization in such patients. We report a 54-year-old diabetic hypertensive male with extensive atherosclerotic coronary and peripheral arterial disease, who presented with congestive heart failure, claudication of both lower limbs and mesenteric ischemia. He underwent successful percutaneous panvascular revascularization of coronary, renal, mesenteric, aorto-iliac and superficial femoral arteries. Long-term patency of all the stents was also documented.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289893 | PMC |
| http://dx.doi.org/10.4330/wjc.v4.i2.48 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: There is a lack of evidence regarding the association between plasma phenylacetylglutamine levels and lesion severity and clinical prognosis in patients with ST-segment elevation myocardial infarction (STEMI) with multivessel coronary disease (MVCD). This study aims to investigate the potential of phenylacetylglutamine as a biomarker for major adverse cardiovascular events (MACEs) of patients with STEMI and MVCD.
Methods And Results: Clinical data and blood samples were collected from 631 patients with STEMI and MVCD, who underwent primary percutaneous coronary intervention.
Miniature Mass Spectrometry for Point-of-Care Testing the GPIIb/IIIa Inhibitor Tirofiban during Perioperative Period of Percutaneous Coronary Intervention.
ACS Omega
December 2024
Panvascular Diseases Research Center, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou 324000, China.
Article Synopsis
- The study developed a portable mass spectrometry technique for accurately measuring tirofiban drug concentrations in blood to enhance patient safety and treatment efficacy.
- The method identified a significant parent ion peak for tirofiban and optimized various parameters, achieving a limit of detection (LOD) and limit of quantification (LOQ) of 10.1 and 33.7 μg·L, respectively.
- Although the technique faced some challenges from blood sample matrix effects, it successfully detected tirofiban in 10 out of 12 clinical samples, demonstrating the need for further optimization and validation to boost sensitivity and stability.
An inflammatory prognostic scoring system to predict the risk for adults with acute coronary syndrome undergoing percutaneous coronary intervention.
BMC Cardiovasc Disord
December 2024
Department of Cardiology, The Affiliated Hospital of Chengde Medical University, No.36, Nanyingzi Street, Shuangqiao District, 067000, Chengde, Hebei Province, China.
Background: This study aimed to investigate the value of the inflammatory prognostic score (IPS) system for predicting the risk of all-cause major adverse cardiovascular events (MACEs) and cardiac-related MACEs in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
Methods: Overall, 1384 patients with ACS who underwent PCI between January 2016 and December 2018 were consecutively enrolled. Demographic characteristics and related laboratory results for 11 inflammatory markers were collected.
Rationale and Design of Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD): A Multicenter, Randomized, Controlled Trial.
Clin Cardiol
December 2024
Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Background: The optimal duration of dual antiplatelet therapy (DAPT) for patients with coronary multi-vessel disease (MVD) who have received drug-eluting stents (DES) remains unclear.
Hypothesis And Methods: The Dual Antiplatelet Therapy in Patients with Coronary Multi-Vessel Disease (DAPT-MVD) study is a multicenter, open-label, randomized controlled trial designed to assess the efficacy and safety of extended DAPT in MVD patients 12 months following DES implantation. We plan to enroll 8250 patients across approximately 100 sites in China.
Long-Term Prognostic Value of Adipocytokines in Patients with Acute Coronary Syndrome: An 8-Year Clinical Prospective Cohort Study.
J Inflamm Res
October 2024
Department of Cardiology, The Affiliated Hospital of Chengde Medical University, Chengde, People's Republic of China.
Purpose: To elucidate the predictive values of adipocytokines in patients with acute coronary syndrome (ACS).
Patients And Methods: Overall, 297 patients with ACS were consecutively enrolled in this prospective cohort study between June 2015 and July 2017 and completed follow-up with a median follow-up time of 6.5 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!